CorMedix reaffirms FY2027 DefenCath guidance $100M-$140M; FY2026 revenue guidance $300M-$320M

CorMedix Inc.

Reaffirms FY2027 DefenCath sales $100M-$140M, correcting inadvertent $100M-$125M range from March 5 earnings call.
FY2026 guidance: revenue $300M-$320M, adjusted EBITDA $100M-$125M, DefenCath sales $150M-$170M.
Q4 2025 net revenue $129M, DefenCath sales $91M; FY2025 pro forma net revenue $401M.
Pipeline milestones: REZZAYO prophylaxis Ph3 data expected Q2 2026; DefenCath TPN (NUTRI-LOCK) data 1H 2027.
Balance sheet at Dec 31 2025: cash & short-term investments $149M, convertible debt $150M, shares outstanding 79.1M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.